carb x seem to be giving polyphor a lot of money for their development of OMPTA outer membrane protein targeting anti biotics.
"Under the extension of the 2019 agreement, CARB-X is committing to Polyphor additional funding of up to USD 2.3 million, bringing potential funding for this contractual stage to USD 5.1 million. Polyphor may also receive up to USD 13 million in future option stages that could take the program through a first-in-human program if certain project milestones are met.“We are delighted to extend our partnership with CARB-X on our OMPTA-BamA program, which has the potential to be a major breakthrough in addressing carbapenem resistance potentially covering all WHO priority 1 pathogens”, said Gokhan Batur, Chief Executive Officer of Polyphor. “This is another important endorsement of Polyphor’s OMPTA program, following the award by CARB-X in October for our OMPTA Thanatin Derivatives program.”Polyphor’s novel OMPTA antibiotics target the highest priority Gram-negative ESKAPE pathogens (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa), which are the leading cause of severe and often deadly infections throughout the world, such as bloodstream infections, urinary tract infections and pneumonia. Importantly, this new class of antibiotics is active against strains which have become resistant to most commonly used antibiotics including the "last resort workhorse" carbapenems."
"CARB-X is investing up to $500 million in antibacterial R&D between 2016-2021. The goal is to support projects through the early phases of development through Phase 1, so that they will attract additional private or public support for further clinical development and approval for use in patients. The scope of CARB-X funding is restricted to projects that target drug-resistant bacteria highlighted on the CDC’s 2013 Antibiotic Resistant Threats list, or the Priority Bacterial Pathogens list published by the WHO in 2017 – with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)